Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Syndax Pharmaceuticals (SNDX) reported a Q4 loss of $1.10 per share, missing the Zacks Consensus Estimate of a $1.08 loss. This is a larger loss compared to $1 per share a year ago.
March 03, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Syndax Pharmaceuticals reported a larger-than-expected Q4 loss of $1.10 per share, missing the consensus estimate of $1.08 and increasing from last year's $1 loss.
The reported loss per share of $1.10 is worse than the expected $1.08, indicating a negative surprise for investors. This, combined with a year-over-year increase in losses, suggests potential short-term downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100